Today at #ESMO26, an oral presentation highlighted the first clinical data for #TILtherapy in two difficult-to-treat soft tissue #sarcomas with limited treatment options. 🧬 Learn more: ir.iovance.com/news-releases…

Iovance showcased three posters at #ESMO26 spanning translational science and health economics and outcomes research across solid tumors. Find these on our website: iovance.com/scientific-publi… #ESMO26 #TILtherapy #CellTherapy

Final Phase 2, lifileucel + pembrolizumab, data explore earlier use of #TILtherapy in frontline melanoma at #ESMO26. Details here: ir.iovance.com/news-releases…

Heading to #ESMO26 this weekend? Stop by the Iovance booth to meet our team and learn more about our commitment to advancing cell therapy for people living with cancer. #Iovance #TILTherapy

Iovance is at #CGTS2026 in NYC 🗽today. Two of our colleagues are joining discussions on cell therapy access, quality, and policy. Thank you @AVBCC for convening the conversation. #CellTherapy #PatientAccess

Madrid, here we come! 🇪🇸 Iovance’s 5 abstracts at #ESMO26 (Oct 23–27) showcase the TIL platform, including 2 orals in frontline advanced melanoma 🔬 and refractory soft tissue sarcomas 🧬 Details here: ir.iovance.com/news-releases…

We’re exhibiting at JADPRO Live 2026. Join us, along with over 1,600 nurse practitioners, physician assistants, clinical nurse specialists, and additional health-care professionals to discuss the innovations in cancer care. Stop by booth #333. #JADPROLive #Celltherapy

Proud Silver Sponsor of #CGMesa26 ☀️🌵Grateful to @alliancerm for bringing the cell & gene therapy community together in Phoenix. Until next year!👏 #CellAndGeneTherapy #CMC

Congratulations to Fred Vogt, PhD, JD, Interim President and CEO of Iovance, on receiving AVBCC’s inaugural Global Cancer Research & Innovation Award, recognizing his contributions to advancing innovation in oncology. Learn more: avbcc.org/avbcc-recognizes-d… 
#AVBCC #Celltherapy

We’re pleased to welcome Noah Berkowitz, M.D., Ph.D., as our Chief Medical Officer. He will lead our global drug development efforts as we continue advancing the Iovance TIL platform across multiple solid tumor cancers. Learn more: ir.iovance.com/news-releases… #CellTherapy

Today we raised our FY2026 total revenue guidance to $410–$420M, driven by strong demand for Amtagvi® and Proleukin®. The midpoint is up $55M from the prior $350–$370M range and implies ~60% annual revenue growth. Full release: ir.iovance.com/news-releases…

This #WorldLungDay, we’re recognizing the continued need for innovation. At Iovance, we're exploring the potential of multiple TIL therapy approaches in metastatic non-small cell lung cancer. Learn more: tilcelltherapy.com/

Cancer research turns unanswered questions into evidence, and evidence into new possibilities for patients. Today, we recognize the researchers, clinicians, patients, and caregivers who make that progress possible. #WorldCancerResearchDay #CellTherapy #CancerResearch

Today, our SVP Global Access, Operations & Proleukin, Anne Brooks, joins @BioBuzz for "The Convergence of Life Sciences & Healthcare Delivery" — a panel on patient access, cell & gene therapy, and AI. #CellTherapy #CGT #PatientAccess

On Saturday, September 26, Team Iovance Bay Area will join @AIMatMelanoma's 8th Annual Steps Against Melanoma Walk at Little Marina Green in San Francisco: support.aimatmelanoma.org/ev… #StepsAgainstMelanoma #AIMatMelanoma

Miles matter.💙Our team walked NYC this Saturday for @CureMelanoma's Miles for Melanoma 5K, standing with the patients, families & advocates who inspire this work. Thank you, MRF! #MilesForMelanoma #MelanomaAwareness

Team Iovance at last year's New York Miles for Melanoma. 💚💙 The @CureMelanoma 5K returns to Pier 84 on Sept 19, and we'll be back on the course! Register: ow.ly/t12x50ZOmIT #MilesForMelanoma #NewYorkNewYork #melanomaresearchfoundation

Brian Gastman, MD, will present at the H.C. Wainwright Global Investment Conference today at 4 PM ET. Watch: ir.iovance.com/news-events/e…

See Jim's story: youtu.be/hBg8udUC_ks?si=jmti…